Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20047581 | 0.85 | TLR8 (0.32) | TLR8KCNH2TLR7NR1H2NR1H3 | |
| SCHEMBL20047554 | 0.79 | GAA (0.38) | NR1H2NR1H3 | |
| SCHEMBL20047580 | 0.79 | GAA (0.38) | NR1H2NR1H3 | |
| SCHEMBL23502449 | 0.77 | NR1H2 (0.33) | NR1H2NR1H3 | |
| SCHEMBL20047490 | 0.76 | NR1H2 (0.35) | NR1H2NR1H3 | |
| SCHEMBL23502475 | 0.73 | TLR8 (0.33) | TLR8KCNH2TLR7 | |
| SCHEMBL23502460 | 0.73 | TLR8 (0.35) | TLR8KCNH2TLR7 | |
| SCHEMBL23502452 | 0.71 | TLR8 (0.34) | TLR8TLR7 | |
| SCHEMBL20989986 | 0.71 | CA2 (0.40) | NR1H2 | |
| SCHEMBL20047567 | 0.71 | CNR2 (0.35) | TLR8KCNH2TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | TLR8 901/4885KCNH2 4528/4885TLR7 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.